These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22485250)

  • 1. ErbB3 expression predicts sensitivity to elisidepsin treatment: in vitro synergism with cisplatin, paclitaxel and gemcitabine in lung, breast and colon cancer cell lines.
    Teixidó C; Arguelaguet E; Pons B; Aracil M; Jimeno J; Somoza R; Marés R; Ramón Y Cajal S; Hernández-Losa J
    Int J Oncol; 2012 Jul; 41(1):317-24. PubMed ID: 22485250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive factors of sensitivity to elisidepsin, a novel Kahalalide F-derived marine compound.
    Serova M; de Gramont A; Bieche I; Riveiro ME; Galmarini CM; Aracil M; Jimeno J; Faivre S; Raymond E
    Mar Drugs; 2013 Mar; 11(3):944-59. PubMed ID: 23519149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epithelial-mesenchymal transition markers and HER3 expression are predictors of elisidepsin treatment response in breast and pancreatic cancer cell lines.
    Teixidó C; Marés R; Aracil M; Ramón y Cajal S; Hernández-Losa J
    PLoS One; 2013; 8(1):e53645. PubMed ID: 23320098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models.
    Ling YH; Aracil M; Jimeno J; Perez-Soler R; Zou Y
    Eur J Cancer; 2009 Jul; 45(10):1855-64. PubMed ID: 19346126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer.
    Yotsumoto F; Fukami T; Yagi H; Funakoshi A; Yoshizato T; Kuroki M; Miyamoto S
    Cancer Sci; 2010 Nov; 101(11):2351-60. PubMed ID: 20726858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.
    Wang S; Huang J; Lyu H; Cai B; Yang X; Li F; Tan J; Edgerton SM; Thor AD; Lee CK; Liu B
    Breast Cancer Res; 2013; 15(5):R101. PubMed ID: 24168763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer.
    Camblin AJ; Pace EA; Adams S; Curley MD; Rimkunas V; Nie L; Tan G; Bloom T; Iadevaia S; Baum J; Minx C; Czibere A; Louis CU; Drummond DC; Nielsen UB; Schoeberl B; Pipas JM; Straubinger RM; Askoxylakis V; Lugovskoy AA
    Clin Cancer Res; 2018 Jun; 24(12):2873-2885. PubMed ID: 29549161
    [No Abstract]   [Full Text] [Related]  

  • 8. ErbB protein modifications are secondary to severe cell membrane alterations induced by elisidepsin treatment.
    Váradi T; Roszik J; Lisboa D; Vereb G; Molina-Guijarro JM; Galmarini CM; Szöllosi J; Nagy P
    Eur J Pharmacol; 2011 Sep; 667(1-3):91-9. PubMed ID: 21658382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling.
    Janmaat ML; Rodriguez JA; Jimeno J; Kruyt FA; Giaccone G
    Mol Pharmacol; 2005 Aug; 68(2):502-10. PubMed ID: 15908515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents.
    Bunn PA; Helfrich B; Soriano AF; Franklin WA; Varella-Garcia M; Hirsch FR; Baron A; Zeng C; Chan DC
    Clin Cancer Res; 2001 Oct; 7(10):3239-50. PubMed ID: 11595720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity.
    Loprevite M; Favoni RE; de Cupis A; Pirani P; Merlo F; Grossi F; Ardizzoni A
    Int J Oncol; 1999 Oct; 15(4):787-92. PubMed ID: 10493963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
    Pegram MD; Konecny GE; O'Callaghan C; Beryt M; Pietras R; Slamon DJ
    J Natl Cancer Inst; 2004 May; 96(10):739-49. PubMed ID: 15150302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in non‑small cell lung cancer cell lines.
    Wang MC; Liang X; Liu ZY; Cui J; Liu Y; Jing L; Jiang LL; Ma JQ; Han LL; Guo QQ; Yang CC; Wang J; Wu T; Nan KJ; Yao Y
    Oncol Rep; 2015 Jan; 33(1):239-49. PubMed ID: 25370413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic anticancer effect of combined use of Trichosanthes kirilowii with cisplatin and pemetrexed enhances apoptosis of H1299 non-small-cell lung cancer cells via modulation of ErbB3.
    Ku JM; Hong SH; Kim HI; Kim MJ; Kim SK; Kim M; Choi SY; Park J; Kim HK; Kim JH; Seo HS; Shin YC; Ko SG
    Phytomedicine; 2020 Jan; 66():153109. PubMed ID: 31790894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Cisplatin, 5-fluorouracil, Irinotecan, and Gemcitabine Treatment in Resistant 2D and 3D Model Triple Negative Breast Cancer Cell Line: ABCG2 Expression Data.
    Ata FK; Yalcin S
    Anticancer Agents Med Chem; 2022; 22(2):371-377. PubMed ID: 34315389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells.
    Kim HJ; Kim HP; Yoon YK; Kim MS; Lee GS; Han SW; Im SA; Kim TY; Oh DY; Bang YJ
    Anticancer Drugs; 2012 Mar; 23(3):288-97. PubMed ID: 23422737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclopamine increases the cytotoxic effects of paclitaxel and radiation but not cisplatin and gemcitabine in Hedgehog expressing pancreatic cancer cells.
    Shafaee Z; Schmidt H; Du W; Posner M; Weichselbaum R
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):765-70. PubMed ID: 16552573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma.
    Voigt W; Kegel T; Weiss M; Mueller T; Simon H; Schmoll HJ
    J Cancer Res Clin Oncol; 2005 Sep; 131(9):585-90. PubMed ID: 16021466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin in combination with zoledronic acid: a synergistic effect in triple-negative breast cancer cell lines.
    Ibrahim T; Liverani C; Mercatali L; Sacanna E; Zanoni M; Fabbri F; Zoli W; Amadori D
    Int J Oncol; 2013 Apr; 42(4):1263-70. PubMed ID: 23403907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpression.
    Konecny GE; Pegram MD
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 12):32-6. PubMed ID: 15685824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.